Vir Biotechnology, Inc. 8-K

What Happened
Vir Biotechnology, Inc. filed a Form 8-K (Item 5.02) reporting that on April 7, 2026 Mark Eisner, MD, MPH, the company's Executive Vice President and Chief Medical Officer, informed the company he will step down from his role effective April 24, 2026. The company has begun a search for his successor.

Key Details

• Filing date: April 10, 2026 (Form 8-K, Item 5.02).
• Announcement date: April 7, 2026; effective date of resignation: April 24, 2026.
• Executive affected: Mark Eisner, MD, MPH — Executive VP & Chief Medical Officer.
• The company has initiated a search for a replacement; the filing does not disclose a successor or transition/compensation details.

Why It Matters
A CMO departure is an executive change that can affect oversight of clinical development and regulatory interactions for biotech companies. For investors, the key facts to watch next are any interim leadership, the named successor, and disclosures about potential impacts on Vir’s clinical programs or timelines. The 8-K provides the official notice of the change but no further details on transition arrangements.